Cabergoline in prolactinomas

Cabergoline is a potent, D2-selective new dopamine agonist with a half-life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparab...

Full description

Saved in:
Bibliographic Details
Published inNeuro-ophthalmology (Amsterdam : Aeolus Press. 1980) Vol. 22; no. 1; pp. 37 - 46
Main Authors Fierz, Anna B., Kaufman, David I., Lee, Andrew G., Eggenberger, Eric R., Friend, Keith E.
Format Journal Article
LanguageEnglish
Published Informa UK Ltd 01.08.1999
Taylor & Francis
Online AccessGet full text

Cover

More Information
Summary:Cabergoline is a potent, D2-selective new dopamine agonist with a half-life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0165-8107
1744-506X
DOI:10.1076/noph.22.1.37.3741